Massey Ventures

The firm does not publicly name a CEO, CIO, or managing director on its website. As a wholly owned university subsidiary, investment decisions likely sit with a management team operating under Massey University's governance structures. An allocator should request the current leadership roster and investment committee charter directly.

Deal flow originates exclusively from Massey University's research community. The firm runs a PreSeed Accelerator for researchers and students, providing both funding and commercial support. It also draws from specific university institutes, such as the Riddet Institute, which produced the FERRI-PRO technology sold to Nestlé.

Neither. It is the wholly owned technology-transfer subsidiary of Massey University. It operates more like a university venture fund and IP licensing office combined, building spin-out companies and negotiating licensing deals rather than managing third-party LP capital.

The firm makes direct investments in spin-out companies and co-invests alongside other New Zealand entities, such as the Matū Fund. It does not market itself as a fund-of-funds, and no evidence suggests it makes LP commitments to external venture funds.

Massey Ventures is a 100% owned subsidiary of the university, created to commercialise its research. It works exclusively with Massey University staff and students, and its most valuable assets are licenses and spin-outs built on university IP. The Massey University Foundation operates as a separate philanthropic arm.

The largest disclosed deal was the 2018 sale of the FERRI-PRO iron technology to Nestlé. Nestlé subsequently used it to launch BUNYAD IRON+, an iron-fortified dairy drink in Pakistan in 2022. Massey Ventures described it as the biggest transaction in university history in both commercial and societal terms.

All known portfolio companies are New Zealand-based. However, its licensing deals reach a global scale — the Nestlé partnership touched Pakistan, and the AFT Pharmaceuticals agreement targets over 100 countries for the strawberry birthmark treatment. The firm's direct investment footprint appears domestic.